Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression

Hejing Bao; Jiani Zhang; Yuhuan Wang; Zhiting Chen; Xi Luo; Ting Li; Haoran Su; Hehong Bao; Xiaolong Cao; Liping Lin

doi:10.3389/fphar.2024.1448291

Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression

Front Pharmacol. 2024 Nov 28:15:1448291. doi: 10.3389/fphar.2024.1448291. eCollection 2024.

Authors

Hejing Bao^#^{1

2}, Jiani Zhang^#³, Yuhuan Wang³, Zhiting Chen³, Xi Luo^{1

2}, Ting Li^{1

2}, Haoran Su^{1

2}, Hehong Bao⁴, Xiaolong Cao^{1

2}, Liping Lin^{1

2}

Affiliations

¹ Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
² Cancer Institute of Panyu, Guangzhou, Guangdong, China.
³ Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
⁴ Department of Psychosomatic Medicine, Chongqing University Three Gorges Hospital, Chongqing, China.

^# Contributed equally.

Abstract

We report a case of an advanced non-small cell lung cancer (NSCLC) patient with brain metastasis, RET fusion, and high expression of programmed death ligand 1 (PD-L1) at initial treatment. After receiving radiotherapy for the brain metastasis, the patient started with anlotinib and added immunotherapy with sintilimab. The patient had a good response to anlotinib and sintilimab treatment, tolerated the adverse reactions, and had a progression-free survival (PFS) of over 17 months. To the best of our knowledge, this is the first clinical case report in the literature describing the benefit of anlotinib and sintilimab treatment for non-small cell lung cancer with RET fusion and high PD-L1 expression. This study explores the biomarker selection for targeted therapy and combined immunotherapy in NSCLC patients.

Keywords: RET fusion; anlotinib; high PD-L1 expression; non-small cell lung cancer; sintilimab.

Publication types

Case Reports

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Panyu Central Hospital project (PY-2023–024), the Panyu District Science and Technology Plan Project (2023-Z04-014) and the Health Science and Technology Project of Guangzhou (20241A011114).